Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*

AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.

Summary  

  • What: AstraZeneca’s intra-country equitable pricing strategy for ticagrelor (Brilinta®) considers five socio-economic factors and targets 27% of priority countries relevant for this product.
  • Objective: The strategy aims to ensure affordability of this product in India, China and Brazil.
  • Details: This relates to AstraZeneca’s heart disease product, ticagrelor (Brilinta®), in Brazil, China and India.
  • Socio-economic factors considered: (1) disease burden, (2) the availability of public financing, (3) levels of inequality, (4) supply chain conditions and (5) patient awareness.

Looking closer

AstraZeneca’s intra-country equitable pricing strategy for ticagrelor (Brilinta®) considers five socio-economic factors: disease burden, the availability of public financing, levels of inequality, supply chain conditions and patient awareness. The strategy targets 27% of priority countries relevant for this product, namely, Brazil, China and India and it targets population segments within these countries. This strategy is particularly important as ticagrelor is used first- line in the prevention of atherothrombotic events. It is also on patent, and AstraZeneca is the only manufacturer.

Sign up to receive updates about our work.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close